SEARCH

SEARCH BY CITATION

References

  • Backman C. M., Shan L., Zhang Y. J., Hoffer B. J., Leonard S., Troncoso J. C., Vonsatel P. and Tomac A. C. (2006) Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson’s disease: a real-time PCR study. Mol. Cell. Endocrinol. 252, 160166.
  • Bal-Price A. and Brown G. C. (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 21, 64806491.
  • Banati R. B. D. S. and Blunt S. B. (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov. Disord. 13, 221227.
  • Bassotti G., Maggio D., Battaglia E., Giulietti O., Spinozzi F., Reboldi G., Serra A. M., Emanuelli G. and Chiarioni G. (2000) Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 68, 768770.
  • Benner E. J., Mosley R. L., Destache C. J., Lewis T. B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S. R., Przedborski S. and Gendelman H. E. (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 101, 94359440.
  • Biasini E., Fioriti L., Ceglia I., Invernizzi R., Bertoli A., Chiesa R. and Forloni G. (2004) Proteasome inhibition and aggregation in Parkinson’s disease: a comparative study in untransfected and transfected cells. J. Neurochem. 88, 545553.
  • Block M. L. and Hong J. S. (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 7798.
  • Chandrasekar I., Stradal T. E., Holt M. R., Entschladen F., Jockusch B. M. and Ziegler W. H. (2005) Vinculin acts as a sensor in lipid regulation of adhesion-site turnover. J. Cell Sci. 118, 14611472.
  • Chartier-Harlin M. C., Kachergus J., Roumier C. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364, 11671169.
  • Choi D. K., Pennathur S., Perier C. et al. (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson’s disease in mice. J. Neurosci. 25, 65946600.
  • Cicchetti F., Brownell A. L., Williams K., Chen Y. I., Livni E. and Isacson O. (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15, 991998.
  • Croisier E., Moran L. B., Dexter D. T., Pearce R. K. and Graeber M. B. (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J. Neuroinflammation 2, 14.
  • Dauer W. and Przedborski S. (2003) Parkinson’s disease: mechanisms and models. Neuron 39, 889909.
  • Dobrenis K. (1998) Microglia in cell culture and in transplantation therapy for central nervous system disease. Methods 16, 320344.
  • Du Y., Ma Z., Lin S. et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 98, 1466914674.
  • El-Agnaf O. M., Salem S. A., Paleologou K. E. et al. (2003) Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 19451947.
  • Fahn S. and Sulzer D. (2004) Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 1, 139154.
  • Fahn S., Clarence-Smith K. E. and Chase T. N. (1998) Parkinson’s disease: neurodegenerative mechanisms and neuroprotective interventions – report of a workshop. Mov. Disord. 13, 759767.
  • Feng Z. H., Wang T. G., Li D. D., Fung P., Wilson B. C., Liu B., Ali S. F., Langenbach R. and Hong J. S. (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329, 354358.
  • Fjorback A. W., Varming K. and Jensen P. H. (2007) Determination of alpha-synuclein concentration in human plasma using ELISA. Scand. J. Clin. Lab. Invest. 67, 431435.
  • Forno L. S. D. L., Irwin I., Di Monte D. and Langston J. W. (1992) Astrocytes and Parkinson’s disease. Prog. Brain Res. 94, 429436.
  • Gao H. M., Hong J. S., Zhang W. and Liu B. (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22, 782790.
  • Ghosh A., Roy A., Liu X., Korodower J. H., Mufson E. J., Mosley R. L., Gendelman H. E., Ghosh S. and Pahan K. (2007) Selective inhibition of NF-kB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc. Natl Acad. Sci. In press.
  • Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985989.
  • Giulian D., Li J., Bartel S., Broker J., Li X. and Kirkpatrick J. B. (1995) Cell surface morphology identifies microglia as a distinct class of mononuclear phagocyte. J. Neurosci. 15, 77127726.
  • Goedert M. (1999) Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 11011118.
  • Goldstein D. S., Eldadah B. A., Holmes C., Pechnik S., Moak J., Saleem A. and Sharabi Y. (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 46, 13331339.
  • Gu Z., Nakamura T., Yao D., Shi Z. Q. and Lipton S. A. (2005) Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson’s disease. Cell Death Differ. 12, 12021204.
  • Halliday G. M., Ophof A., Broe M., Jensen P. H., Kettle E., Fedorow H., Cartwright M. I., Griffiths F. M., Shepherd C. E. and Double K. L. (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson’s disease. Brain 128, 26542664.
  • Hong J. S. (2005) Role of inflammation in the pathogenesis of Parkinson’s disease: models, mechanisms, and therapeutic interventions. Ann. NY Acad. Sci. 1053, 151152.
  • Hornykiewicz O. and Kish S. J. (1987) Biochemical pathophysiology of Parkinson’s disease. Adv. Neurol. 45, 1934.
  • Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y. and Taniguchi T. (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417, 5967.
  • Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106108.
  • Kurkowska-Jastrzebska I., Litwin T., Joniec I., Ciesielska A., Przybylkowski A., Czlonkowski A. and Czlonkowska A. (2004) Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson’s disease. Int. Immunopharmacol. 4, 13071318.
  • Laurie C., Reynolds A., Coskun O., Bowman E., Gendelman H. E. and Mosley R. L. (2007) CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J. Neuroimmunol. 183, 6068.
  • Lee H. J., Patel S. and Lee S. J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 60166024.
  • Liu B. and Hong J. S. (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304, 17.
  • Liu Y., Liu J., Tetzlaff W., Paty D. W. and Cynader M. S. (2006) Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic. Biol. Med. 40, 960967.
  • Mandel S. G. E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G. and Youdim M. B. (2005) Gene expression profiling of sporadic Parkinson’s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. NY Acad. Sci. 1053, 356375.
  • Mayeux R. (2003) Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26, 81104.
  • McGeer P. L. and McGeer E. G. (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 12(Suppl. 2), S1S6.
  • McGeer P. L. and McGeer E. G. (2004) Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat. Disord. 10(Suppl. 1), S3S7.
  • McLaughlin P., Zhou Y., Ma T., Liu J., Zhang W., Hong J. S., Kovacs M. and Zhang J. (2006) Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 53, 567582.
  • Meini A., Garcia J. B., Pessina G. P., Aldinucci C., Frosini M. and Palmi M. (2006) Role of intracellular Ca2+ and calmodulin/MAP kinase kinase/extracellular signal-regulated protein kinase signalling pathway in the mitogenic and antimitogenic effect of nitric oxide in glia- and neurone-derived cell lines. Eur. J. Neurosci. 23, 16901700.
  • Mirza B. H. H., Thomsen P. and Moos T. (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson’s disease. Neuroscience 95, 425432.
  • Parente L. and Solito E. (2004) Annexin 1: more than an anti-phospholipase protein. Inflamm. Res. 53, 125132.
  • Przedborski S., Chen Q., Vila M., Giasson B. I., Djaldatti R., Vukosavic S., Souza J. M., Jackson-Lewis V., Lee V. M. and Ischiropoulos H. (2001) Oxidative post-translational modification of alpha-synuclein in the 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease. J. Neurochem. 76, 637640.
  • Qin L., Wu X., Block M. L., Liu Y., Breese G. R., Hong J. S., Knapp D. J. and Crews F. T. (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55, 453462.
  • Reynolds A. D., Banerjee R., Liu J., Gendelman H. E. and Mosley R. L. (2007) Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J. Leukoc. Biol. 82, 10831094.
  • Singleton A. B., Farrer M., Johnson J. et al. (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302, 841.
  • Souza J. M., Giasson B. I., Chen Q., Lee V. M. and Ischiropoulos H. (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 1834418349.
  • Spira P. J., Sharpe D. M., Halliday G., Cavanagh J. and Nicholson G. A. (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49, 313319.
  • Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839840.
  • Sriram K., Matheson J. M., Benkovic S. A., Miller D. B., Luster M. I. and O’Callaghan J. P. (2002) Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J. 16, 14741476.
  • Sung J. Y., Park S. M., Lee C. H., Um J. W., Lee H. J., Kim J., Oh Y. J., Lee S. T., Paik S. R. and Chung K. C. (2005) Proteolytic cleavage of extracellular secreted α-synuclein via matrix metalloproteinases. J. Biol. Chem. 280, 2521625224.
  • Taki J., Nakajima K., Hwang E. H., Matsunari I., Komai K., Yoshita M., Sakajiri K. and Tonami N. (2000) Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific, taki@med.kanazawa-u.ac.jp. Eur. J. Nucl. Med. 27, 566573.
  • Tanner C. M. (1992) Occupational and environmental causes of parkinsonism. Occup. Med. 7, 503513.
  • Teismann P. and Ferger B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse 39, 167174.
  • Teismann P., Tieu K., Choi D. K., Wu D. C., Naini A., Hunot S., Vila M., Jackson-Lewis V. and Przedborski S. (2003) Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 54735478.
  • Thomas M. P., Chartrand K., Reynolds A., Vitvitsky V., Banerjee R. and Gendelman H. E. (2007) Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson’s disease. J. Neurochem. 100, 503519.
  • Vijitruth R., Liu M., Choi D. Y., Nguyen X. V., Hunter R. L. and Bing G. (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J. Neuroinflammation 3, 6.
  • Vilhardt F. (2005) Microglia: phagocyte and glia cell. Int. J. Biochem. Cell Biol. 37, 1721.
  • Vuadens F., Rufer N., Kress A., Corthesy P., Schneider P. and Tissot J. D. (2004) Identification of swiprosin 1 in human lymphocytes. Proteomics 4, 22162220.
  • Walther M., Kuklinski S., Pesheva P., Guntinas-Lichius O., Angelov D. N., Neiss W. F., Asou H. and Probstmeier R. (2000) Galectin-3 is upregulated in microglial cells in response to ischemic brain lesions, but not to facial nerve axotomy. J. Neurosci. Res. 61, 430435.
  • Wang X., Chen S., Ma G., Ye M. and Lu G. (2005) Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech. Ageing Dev. 126, 12411254.
  • Wersinger C. and Sidhu A. (2006) An inflammatory pathomechanism for Parkinson’s disease? Curr. Med. Chem. 13, 591602.
  • Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H. and Przedborski S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 17631771.
  • Wu D. C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H. and Przedborski S. (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 100, 61456150.
  • Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164173.
  • Zbarsky V., Datla K. P., Parkar S., Rai D. K., Aruoma O. I. and Dexter D. T. (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radic. Res. 39, 11191125.
  • Zhang W., Wang T., Pei Z., Miller D. S., Wu X., Block M. L., Wilson B., Zhou Y., Hong J. S. and Zhang J. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 19, 533542.
  • Zhou Y., Wang Y., Kovacs M., Jin J. and Zhang J. (2005) Microglial activation induced by neurodegeneration: a proteomic analysis. Mol. Cell Proteomics 4, 14711479.